Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 10, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It is not a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.1861 per share.
- Transaction Volume: 16 shares per individual (comprising 8 partnership shares and 8 matching shares).
- Transaction Date: August 9, 2017.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses routine acquisitions of shares under the Company's Share Reward Plan by nine senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific equity transactions.
Important Facts for Investors
- Executive Participation: Nine senior executives participated in the Share Reward Plan on August 9, 2017, including CEO Emma Walmsley, CFO Simon Dingemans, and President of R&D Peter Vallance.
- Transaction Nature: All transactions were acquisitions of ordinary shares, split evenly between partnership shares and matching shares.
- Uniform Pricing: All listed executives acquired shares at the identical price of £15.1861.
- Volume: The total volume per executive was minimal (16 shares), indicating these are likely vesting or matching contributions rather than open market purchases.